Evidence map›Paper›PMID 32015762›Full record

ArticleDiabetology & metabolic syndrome2020

Association between metabolic syndrome and prognosis of breast cancer: a meta-analysis of follow-up studies.

Peiting Li, Tianying Wang, Chen Zeng, Meng Yang, Gang Li, Jiang Han, Wei Wu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetology & metabolic syndrome, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Metabolic Syndrome and Risks of Breast Cancer Outcomes for Luminal, Triple-Negative, and HER2-Overexpressing Subtypes.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Peiting Li1Department of Breast Thyroid Surgery, The Third Xiangya Hospital of Central South University, No. 172 Tong Zi Po Road, Changsha, 410013 China.
Tianying Wang2Department of Hepatopancreatobiliary Surgery, The Third Xiangya Hospital of Central South University, No. 172 Tong Zi Po Road, Changsha, 410013 China.
Chen Zeng1Department of Breast Thyroid Surgery, The Third Xiangya Hospital of Central South University, No. 172 Tong Zi Po Road, Changsha, 410013 China.
Meng Yang1Department of Breast Thyroid Surgery, The Third Xiangya Hospital of Central South University, No. 172 Tong Zi Po Road, Changsha, 410013 China.
Gang Li1Department of Breast Thyroid Surgery, The Third Xiangya Hospital of Central South University, No. 172 Tong Zi Po Road, Changsha, 410013 China.
Jiang Han1Department of Breast Thyroid Surgery, The Third Xiangya Hospital of Central South University, No. 172 Tong Zi Po Road, Changsha, 410013 China.
Wei Wu1Department of Breast Thyroid Surgery, The Third Xiangya Hospital of Central South University, No. 172 Tong Zi Po Road, Changsha, 410013 China.
Third Xiangya Hospital · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetabolic syndrome (MetS) has been suggested to be a risk factor for many cancers, including breast cancer. However, it remains unclear whether MetS predicts poor prognosis in women with breast cancer. A meta-analysis was performed to summarize the association between MetS and clinical outcome in women with breast cancer.

methodsCohort studies were identified by search of PubMed and Embase databases. A random-effect model incorporating the potential heterogeneity was applied to pool the results. Subgroup analyses according to the ethnicity and study design were performed.

resultsNine cohort studies with 17,892 women with breast cancer were included. Pooled results showed that MetS was significantly associated with an increased risk of breast cancer recurrence (adjusted risk ratio [RR] = 1.52, 95%, p = 0.02). Subgroup analyses showed that MetS was independently associated with increased recurrence of breast cancer in Caucasians (adjusted RR = 1.75, p = 0.02), but not in Asians (adjusted RR = 1.07, p = 0.81), and MetS was associated with a trend of increased risk of breast cancer recurrence in both the prospective and retrospective studies. Although we failed to show a significant association between MetS and breast cancer related deaths (adjusted RR = 1.24, p = 0.41), MetS was associated with increased risk of all-cause deaths in these patients (adjusted RR = 1.80, p < 0.001).

conclusionsMetS may predict the risk of cancer recurrence and mortality in women with breast cancer, particularly in Caucasians.

Indexed as

Breast cancerMeta-analysisMetabolic syndromeMortalityRecurrence

Identifiers

PMID32015762
PMCPMC6990514
OpenAlexW3004621110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.